Table 5. Phase III adjuvant chemoradiation trials for adenocarcinoma of the pancreatic head.
| Trial | Treatment | n | % Stage ≥T3/%node (+) | Median survival (months) |
|---|---|---|---|---|
| GITSG (1987) | Observation | 22 | 35/28% | 10.9 |
| 40 Gy+5-FUa | 21 | 20.0 | ||
| EORTC (Klinkenbijl et al, 1999) | Observation | 60 | 0/47% | 12.6 |
| 40 Gy+5-FUb | 54 | 17.1 | ||
| ESPAC (Neoptolemos et al, 2004) | Observation | 69 | 16.9 | |
| 6 Cycles 5-FU | 75 | 30/59% | 21.6 | |
| 40 Gy+5-FUb | 73 | 13.9 | ||
| 40 Gy+5-FUc | 72 | 19.9 | ||
| *WFU/Lyon (phase II) | 50 Gy+ Gemcitabined | 47 | 74/70% | 18.3 |
a
Patients received 5-FU (2 doses) during the radiation followed by 2 years of monthly therapy.
b
Patients received 5-FU (2 doses) during the radiation only.
c
Patients received 5-FU (2 doses) during the radiation followed by six additional months of 5-FU therapy.
d
Patients received Gemcitabine (12 doses) during the radiation followed by two additional months of Gemcitabine.
5-FU, 5-fluorouracil.